Ticker Symbol: PSTI
Pluri Inc
$2.79 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
Israel
Currency:
USD
Asset
Type: Common Stock
CIK:0001158780
Company Profile
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: Matam Advanced Technology Park
Website: www.pluristem.com
CEO: Yaky Yanay
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Pricing
Last Updated: December 31, 1969 07:00 PM EST
Previous Close: -
Change:
-$0.03
(
-2.91%)
Days Range: $0.95 - $1.05
Beta: 1.04
52wk. High: $3.45
52wk. Low: $0.95
Ytd. Change -34.42%
50 Day Moving Average: $1.20
200 Day Moving Average: $1.61
Shares Outstanding: 32347584
Valuation
Market Cap: 3.2B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A